skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Xentuzumab (Code C106118)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Xentuzumab

NCI-DEFCURATOR Definition: A humanized IgG1 insulin-like growth factor (IGF) monoclonal antibody targeting the IGF ligands 1 (IGF-1) and 2 (IGF-2), with potential antineoplastic activity. Upon administration, xentuzumab binds to both IGF-1 and IGF-2 and inhibits the binding of these ligands to their receptor, IGF-1R. This blocks the insulin growth factor (IGF) signaling pathway, which is upregulated in a number of cancer cell types and plays a key role in cancer cell proliferation and chemoresistance. In addition, BI 836845 prevents the binding of IGF-2 to insulin receptor variant A (IR-A), preventing its activation.

Display Name: Xentuzumab

Label: Xentuzumab

NCI Thesaurus Code: C106118 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3827152  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
BI 836845
Immunoglobulin G1, Anti-(Human Insulin-like Growth Factor I) (Human Monoclonal PS05388 Heavy Chain), Disulfide with Human Monoclonal PS05388 Light Chain, Dimer

External Source Codes: 
CAS Registry Number 1417158-65-6 (see NLM ChemIDplus info)
FDA UNII Code X86Z1O656G
PDQ Closed Trial Search ID 697680
PDQ Open Trial Search ID 697680 (check for NCI PDQ open clinical trial info)
UMLS CUI C3827152

Other Properties:
     Name Value (qualifiers indented underneath)
code C106118
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom